Goldman Sachs
MITO

Goldman Sachs’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Goldman Sachs’s Portfolio MITO Stock Details MITO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-88,426
Closed -$138K – 6653
2021
Q2 		$138K Buy
+88,426
New +$123K ﹤0.01% 5867
2021
Q1 		– Sell
-14,989
Closed -$22K – 6455
2020
Q4 		$22K Buy
+14,989
New +$21K ﹤0.01% 5434

Other funds holding MITO

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
SBL
Sargent Bickham Lagudis Boulder, Colorado $1.22B AUM 14.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs's MITO Position: Q3 2021 in Review

Goldman Sachs sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q3 2021, closing a stake of 88,426 shares — an estimated $138K sold.

Goldman Sachs first reported a position in MITO in Q4 2020 and held it in 2 quarters. The position peaked at $138K in Q2 2021. 14 funds tracked by Wall St. Rank hold MITO as of Q3 2021.

  • Goldman Sachs reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q3 2021 after selling out during the quarter.
  • Goldman Sachs sold 88,426 Stealth BioTherapeutics Corp. ADS shares in Q3 2021, an estimated $138K.
  • Goldman Sachs first reported a position in Stealth BioTherapeutics Corp. ADS in Q4 2020 and held it in 2 quarters.
  • Goldman Sachs's Stealth BioTherapeutics Corp. ADS position peaked at $138K in Q2 2021.
  • 14 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q3 2021.

Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.